{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"COMPASS Pathways Plc"},"Symbol":{"label":"Symbol","value":"CMPS"},"Address":{"label":"Address","value":"33 BROADWICK STREET,3RD FLOOR, LONDON, W1F 0DQ, United Kingdom"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360."},"CompanyUrl":{"label":"Company Url","value":"https://www.compasspathways.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Greg Ryslik","title":"Chief Technology Officer"},{"name":"Guy Goodwin","title":"Chief Medical Officer"},{"name":"Kabir Kumar Nath","title":"Chief Executive Officer & Director"},{"name":"Michael Gold","title":"Chief Research & Development Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}